Published in Medical Devices: Evidence and Research

Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor

St. Peter DM, Steger JS, Patnaik JL, Davis N, Kahook MY, Seibold LK

doi: 10.2147/MDER.S397654. Published Apr 2023.



Nanodropper extends bottle-life by 2.6x

Published in *Ophthalmology*

AMERICAN ACADEMY™ OF OPHTHALMOLOGY

Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children

Hoppe CB, Yonamine S, Kao BW, Turner ML, Ou Y, Han Y, Keenan JD, Oatts JT

doi: 10.1016/j.ophtha.2022.10.016. Published Mar 2023.

Clinicaltrials.gov: NCT05274321



Non-inferiority of mydriatic microdrops established for maximum pupil diameter

Published in *Ophthalmology*

AMERICAN ACADEMY™ OF OPHTHALMOLOGY

An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®

Steger JS, Durai I, Odayappan A, Raman R, Sruthi T, Song AJ, Puthuran G, Venkatesh R, Colantuoni E, Robin AL

doi: https://doi.org/10.1016/j.ophtha.2024.03.012. Published Mar 2024.

Clinicaltrials.gov: NCT05181046





No between-group difference in IOP at any time point

Microdrops reduced HR significantly less than conventional drops

Twelve-Week Randomized, Controlled, Non-Inferiority Trial Evaluating the Safety and Efficacy of IOP-Lowering Microdrops Administered with the Nanodropper® Adaptor in Glaucoma Patients

Steger JS, Capó-Aponte JE, Papp A, Schulte AJ, Song AJ, Colantuoni E, Kelstrom JC

Presented at ARVO 2024

Manuscript in preparation

Clinicaltrials.gov: NCT05844384

Mean intraocular pressure (IOP) at baseline and 12 weeks[a]

	Conventional drops (n = 30)	Microdrops (n = 29)	Microdrops – Conventional drops (n = 29)	
IOP, mm Hg			Mean difference (95% CI)	Met non-inferiority criteria
Baseline	16.37 ± 2.85			
12 weeks	16.23 ± 2.78	14.93 ± 2.94	-1.41 (-2.09 to -0.73)*	Yes
Change from baseline	-0.13 (-0.52 to 0.26)	-1.59 (-2.29 to -0.88)*	-1.41 (-2.09 to -0.73)*	
% Change from baseline	-0.56 (-2.89 to 1.77)	-9.35 (-13.44 to -5.26)*	-8.48 (-12.48 to -4.49)*	

[a]Values are expressed as mean ± SD or mean (95% CI)
*p<0.05



- Non-inferiority and superiority of microdrops established
- In stable glaucoma patients, microdrops decreased IOP from baseline by 1.6 mm Hg

Early bottle exhaustion (EBE)



Adverse events (AEs)



At 12 weeks

- Microdrops decreased EBE prevalence by 80%[b]
- Microdrops decreased AE prevalence by 67%[b]

[b]Relative to conventional drops at 12 weeks.
*p<0.05

Learn more at nanodropper.com